# US 2026/0242503 A1 · Methods of Treating High Risk Multiple Myeloma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0242503 A1
- Document ID: US20260242503A1
- Status: Published application
- Kind: A1
- Application number: 19/666,147
- Filed: 2026-05-01
- Published: 2026-08-20
- Earliest claimed: 2017-10-31
- Assignees: Janssen Biotech, Inc.
- Applicants: Janssen Biotech, Inc.
- Inventors: Tahamtan Ahmadi; Christopher Chiu; Ming Qi; Amy Sasser; Jordan Schecter
- Web page: https://patentgrep.com/patent/US20260242503A1

## CPC

- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/69: Boron compounds
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- G01N 33/57505: of the blood, e.g. leukaemia
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N 2800/54: Determining the risk of relapse
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.

## Claims

### Claim 1

A method of treating multiple myeloma in a subject that had received two prior therapies, comprising administering to the subject a combination regimen comprising a therapeutically effective amount of daratumumab, bortezomib, and dexamethasone,
wherein the subject achieves a complete response (CR);
wherein the subject is minimal residual disease (MRD) negative after at least 6 months of achieving the CR;
wherein the subject exhibits progression-free survival (PFS) of at least 16 months following initiation of the combination regimen; and
wherein the method increases PFS compared to administering dexamethasone and bortezomib without the daratumumab.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method increases overall response rate (ORR) compared to administering dexamethasone and bortezomib without the daratumumab.

### Claim 3 (depends on 2)

The method of claim 2, wherein the method increases rate of very good partial response (VGPR) or better compared to administering dexamethasone and bortezomib without the daratumumab.

### Claim 4 (depends on 1)

The method of claim 1, wherein the MRD is determined at a sensitivity threshold of 0.0001%.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject has had autologous stem cell transplantation (ASCT).

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject achieves a stringent complete response.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject had received a proteasome inhibitor as one of the two prior therapies.

### Claim 8 (depends on 7)

The method of claim 7, wherein the proteasome inhibitor is bortezomib.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject had received an immunomodulatory agent as one of the two prior therapies.

### Claim 10 (depends on 9)

The method of claim 9, wherein the immunomodulatory agent is lenalidomide.

### Claim 11 (depends on 1)

The method of claim 1, wherein the subject has relapsed or refractory multiple myeloma.

### Claim 12 (depends on 11)

The method of claim 11, wherein the subject is refractory to lenalidomide.

### Claim 13 (depends on 11)

The method of claim 11, wherein the subject is refractory to bortezomib.

### Claim 14

A method of treating relapsed or refractory multiple myeloma in a subject that had received two prior therapies, comprising administering to the subject a combination regimen comprising a therapeutically effective amount of daratumumab, lenalidomide, and dexamethasone,
wherein the subject achieves a CR;
wherein the subject is MRD negative after at least 6 months of achieving the CR;
wherein the subject exhibits PFS of at least 21 months following initiation of the combination regimen;
and
wherein the method increases PFS compared to administering dexamethasone and lenalidomide without the daratumumab.

### Claim 15 (depends on 14)

The method of claim 14, wherein the method increases ORR compared to administering dexamethasone and lenalidomide without the daratumumab.

### Claim 16 (depends on 15)

The method of claim 15, wherein the method increases rate of VGPR or better compared to administering dexamethasone and lenalidomide without the daratumumab.

### Claim 17 (depends on 15)

The method of claim 15, wherein the method increases rate of CR or better compared to administering dexamethasone and lenalidomide without the daratumumab.

### Claim 18 (depends on 14)

The method of claim 14, wherein the MRD is determined at a sensitivity threshold of 0.0001%.

### Claim 19 (depends on 14)

The method of claim 14, wherein the subject has had ASCT.

### Claim 20 (depends on 14)

The method of claim 14, wherein the subject had received a proteasome inhibitor as one of the two prior therapies.

### Claim 21 (depends on 20)

The method of claim 20, wherein the proteasome inhibitor is bortezomib.

### Claim 22 (depends on 14)

The method of claim 14, wherein the subject had received an immunomodulatory agent as one of the two prior therapies.

### Claim 23 (depends on 22)

The method of claim 22, wherein the immunomodulatory agent is lenalidomide.

### Claim 24 (depends on 14)

The method of claim 14, wherein the subject is refractory to lenalidomide.

### Claim 25 (depends on 14)

The method of claim 14, wherein the subject is refractory to bortezomib.
